Non-Hodgkin lymphoma (NHL) is a heterogeneous group of cancers that comprise 90% of lymphomas, the majority (85%–90%) originating from B lymphocytes;[1] NHL includes indolent forms (e.g. follicular lymphoma [FL]), as well as aggressive forms (e.g. diffuse large B-cell lymphoma [DLBCL]). Although NHL is highly responsive to standard front-line immunochemotherapy, which includes the anti-CD20 antibody, rituximab, with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP),[2] many patients will relapse, develop refractory disease, or develop rituximab resistance.[2,3] Despite clear improvements in outcome in the post-rituximab era, prognosis for patients in the relapsed/refractory setting remains poor, with one study reporting a median overall survival (OS) of only 0.7 months in DLBCL patients with progressive disease following initial R-CHOP therapy.[2] In addition, chemotherapy regimens are highly aggressive and the associated side effects can reduce efficacy and quality of life in some patients, making less toxic agents desirable.
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study / Zinzani, Pl; Rigacci, L; Cox, Mc; Devizzi, L; Fabbri, A; Zaja, F; Di Rocco, Alice; Rossi, G; Storti, S; Fattori, Pp; Argnani, L; Vitolo, U.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - (2017), pp. 226-229. [10.1080/10428194.2016.1184755]
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
DI ROCCO, Alice;
2017
Abstract
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of cancers that comprise 90% of lymphomas, the majority (85%–90%) originating from B lymphocytes;[1] NHL includes indolent forms (e.g. follicular lymphoma [FL]), as well as aggressive forms (e.g. diffuse large B-cell lymphoma [DLBCL]). Although NHL is highly responsive to standard front-line immunochemotherapy, which includes the anti-CD20 antibody, rituximab, with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP),[2] many patients will relapse, develop refractory disease, or develop rituximab resistance.[2,3] Despite clear improvements in outcome in the post-rituximab era, prognosis for patients in the relapsed/refractory setting remains poor, with one study reporting a median overall survival (OS) of only 0.7 months in DLBCL patients with progressive disease following initial R-CHOP therapy.[2] In addition, chemotherapy regimens are highly aggressive and the associated side effects can reduce efficacy and quality of life in some patients, making less toxic agents desirable.File | Dimensione | Formato | |
---|---|---|---|
Zinzani_efficacy-lenalidomide_2016.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
791.51 kB
Formato
Adobe PDF
|
791.51 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.